Evaluation of urinary 6-hydroxymelatonin sulphate excretion in women at different age with irritable bowel syndrome

• Autorzy: Wisniewska-Jarosinska M. , Chojnacki J. , Konturek S. , Brzozowski T. , Smigielski J. , Chojnacki C.
• Języki publikacji: EN

Abstrakty

EN

Melatonin (MT) exerts a beneficial action in the treatment of many diseases, among them also in irritable bowel syndrome (IBS). Its secretion decreases with age, particularly, in the postmenopausal period in women. It has not been determined whether these changes can have an impact on the clinical picture of IBS. The study aimed at evaluating the urinary excretion of the main MT metabolite - 6-hydroxymelatonin sulphate (6-HMS) in women at different age with IBS. The investigations were carried out in five groups of 30 women each. Group Ia (the controls) – premenopausal healthy women (20-39 years), group Ib (the controls) – postmenopausal healthy women (46-66 years), group II – women with constipation predominant IBS (IBS-C; 19-42 years), group III – women with diarrhoea predominant IBS (IBS-D; 20-39 years), group IV- women with IBS-C (49-68 years), group V – women with IBS-D (48-69 years). The diagnosis of IBS was based on the Rome III Criteria after excluding other diseases. On the day of the study the patients remained on the same liquid diet (Nutridrink – 3x400 ml) and 1500 ml of still mineral water. 6-HMS concentration in urine was measured by ELISA method applying IBL antibodies (RE-54031, Immunological Laboratories). The results showed that 24-hour urinary 6-HMS excretion in the studied premenopausal women were as follows: group Ia – 15.13±5.83 µg/24 h, group II – 28.85±12.59 µg/24 h (p<0,01), group III – 26.10±11.76 µg/24 h (p<0,01) and in the postmenopausal subjects they were: group Ib – 10.66±3.23 µg/24 h, group IV – 13.73±5.09 µg/24 h ((p=0,02), group V – 21.39±10.88 µg/24 h (p<0,01). In women with IBS-C the obtained results of 24-hour 6-HMS urinary excretion were independent on the intensity of clinical symptoms. On the other hand, in women with IBS-D, both in the group III and V, higher intensity of ailments was accompanied by significantly increased 6-HMS urinary excretion. The results of the study allowed drawing the following conclusions: (1). 24-hour 6-HMS urinary excretion in women with the constipation-predominant (IBS-C) as well as the diarrhoea-predominant IBS (IBS-D) is higher than in healthy persons both in the premenopausal and postmenopausal period. (2). Relatively high 6-HMS urinary excretion in postmenopausal women with IBS-D indicates an adaptive increase in MT secretion from EC in the gut.

Słowa kluczowe

EN

6-hydroxymelatonin sulphate; melatonin; excretion; urinary excretion; irritable bowel syndrome; premenopausal woman; postmenopausal woman; woman; tumour necrosis factor-alpha; nuclear factor-kappaB; interleukin 6

• Wydawca: -
• Czasopismo: Journal of Physiology and Pharmacology
• Rocznik: 2010
• Tom: 61
• Numer: 3
• Opis fizyczny: p.295-300,fig.,ref.

Twórcy

autor

Wisniewska-Jarosinska M.

• Medical University of Lodz, 1 Haller Square, 90-647 Lodz, Poland

autor

Chojnacki J.

autor

Konturek S.

autor

Brzozowski T.

autor

Smigielski J.

autor

Chojnacki C.

Bibliografia

• Mahadewa S, Goh KH. Epidemiology of functional dyspepsia: a global perspective. Worl J Gastroenterol 2006; 12: 2661-2666.
• Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132: 397-414.
• Thor PJ, Krolczyk G, Gil K, Zurowski D, Nowak L. Melatonin and serotonin effects on gastrointestinal motility. J Physiol Pharmacol 2007; 57(Suppl. 6): 97-103.
• Gershon MD. Review article: roles played by 5-hydroksytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13: 15-30.
• Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000; 95: 2698-2709.
• Reiter RJ, Parades SD, Manchester LC, Tan DX. Reducing oxidative/nitrosative stress: a newly discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009; 44: 175-200.
• Reiter RJ, Tan DX, Mayo JC, Sainz RM, Leon J, Czarnocki Z. Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim Pol 2003; 50: 1129-1146.
• Murawska-Cialowicz E, Januszewska L, Zuwala-Jagiello J, et al. Melatonin decreases homocysteine level in blood of rats. J Physiol Pharmacol 2008; 59(4): 717-729.
• Reiter RJ, Tan DX, Mayo M, Sainz RM, Leon J, Bandyopadhyay D. Neurally mediated and neurally independant beneficial action of melatonin in the gastrointestinal tract. J Physiol Pharmacol 2003; 54(Suppl 4): 111-125.
• Cabeza JA, Alarcon-de-la-Lastra C, Jimenez Z, Martin MJ, Motilva V. Melatonin modulates the effects of injury in rats: role of prostaglandins and nitric oxide. Neurosignals 2003; 12: 71-77.
• Konturek PC, Celinski K, Slomka M, et al. Melatonin and its precursor L-tryptophan prevent acute gastric mucosal damage induced by aspirin in humans. J Physiol Pharmacol 2008; 59(Suppl 2): 67-75.
• Kasimay O, Cakir B, Devseren E, Yegen BC. Exogenous melatonin delays fasting emptying rate in rats: role of CCK2 and 5-HT3 receptors. J Physiol Pharmacol 2005; 56: 543-553.
• Stewart JW, Quitkin FM, Terman M, Terman JS. Is seasonal affective disorder a variant of atypical depression? Differential response to light therapy. Psychiatry 1990; 33: 121-128.
• Mayer LA. The neurobiology of stress and gastrointestinal disorders. Gut 2000; 47: 861-869.
• Rosenthal NE. Melatonin in seasonal affective disorder and phototherapy. J Neurol Transm 1986; Suppl 21: 257-267.
• Karasek M, Reiter RJ. Melatonin and aging. Neuroendocrinol Lett 2002; 23(Suppl 1): 14-16.
• Okatani Y, Marioka N, Wakatsuki A. Changes in nocturnal melatonin secretion in perimenopausal women: correlation with endogenous estrogen concentrations. J Pineal Res 2000; 20: 111-118.
• Vakkuri O, Kivela A, Leppaluoto J, Valtonen M, Kauppila A. Decrease in melatonin precedes follicle-stimulating hormone increase during perimenopause. Eur J Endocrinol 1996; 135: 188-192.
• Baskett JJ, Cockrem JF, Antunowich TA. Sulphatoxy-melatonin excretion in older people: relationship to plasma melatonin and renal function. J Pineal Res 1998; 24: 58-61.
• Arendt J, Bojkowski C, Franey C, Wright J, Marks V. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocrinol Metab 1985; 60: 1166-1173.
• Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia M et al. Light/dark patterns of interleukin 6 in relation to the pineal hormone melatonin in patients with acute myocardial infarction. Cytokine 2004; 21: 89-93.
• Bubenik GA. Thirty four years since discovery of gastrointestinal melatonin. J Physiol Pharmacol 2008; 59(Suppl 2): 33-51.
• Bubenik GA, Brown GM. Pinealectomy reduces melatonin levels in the serum but not in the gastrointestinal tract of rats. Biol Signals 1997; 6: 40-44.
• Sjoblom M, Jedstedt G, Flemstrom G. Peripheral melatonin mediates neural stimulation of duodenal bicarbonate secretion. J Clin Invest 2001; 108(4): 625-633.
• Reiter RJ, Tan DX. Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions. Acta Biochim Pol 2007; 54: 1-9.
• Peyrot F, Ducrocq C. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J Pineal Res 2008; 45: 235-246.
• Reiter RJ, Tan DX, Manchester LC, Paredes SD, Mayo JC, Sainz RM. Melatonin and reproduction revisited. Biol Reprod 2009; 81: 445-456.
• Ronnberg L, Kauppila A, Leppaluoto J. Cicardian and seasonal variation in human preovulatory follicular fluid melatonin concentration. J Clin Endocrinol Metab 1990; 71: 492-496.
• Itoh MT, Ishizuka B, Kuribayashi Y, Amemiya A, Sumi Y. Melatonin, its precursors, and synthesizing enzyme activities in the human ovary. Med Hum Reprod 1999; 5: 402-408.
• Boddis J, Koppan M, Kornya L, Tinneberg HR, Torok A. Influence of melatonin on basal and gonadotropin-stimulated progesterone and estradiol secretion of cultured human granulosa cells and in the superfused granulosa cells system. Gynecol Obstet Invest 2001; 52: 198-202.
• Yie SM, Brown GM, Lin GY, et al. Melatonin and steroids in human pre-ovulatory follicular fluid: seasonal varriations and granulosa cell steroid production. Hum Reprod 1995; 10: 30-55.
• Luboshitzky A, Levi M, Shen-Orr Z. Long-term melatonin administration does not alter pituitary-gonadal hormone secretion in normal man. Hum Reprod 2000; 15: 60-65.
• Reiter RJ. The pineal gland and its hormones in the control reproduction in mammals. Endocrinol Res 1980; 7: 109-131.
• Bubenik GA. Localization, physiological significance and possible clinical implication of gastrointestinal melatonin. Biol Signal Recept 2001; 10: 350-360.
• Reyes-Vazquez C, Naranjo-Rodriguez EB, Garcia-Segoviano JA, Trujillo-Santana JT, Prieto-Gomez B. Apamin blocks the direct relaxant effect of melatonin on rat ileal smooth muscle. J Pineal Res 1997; 22: 1-8.
• Forester ER, Green T, Elliot M, Bremner A, Dockray GJ. Gastric emptying in rats: role of afferent neurons and cholecystokinin. Am J Physiol 1990; 258: 552-556.
• Barajas-Lopez C, Peres AL, Espinosa-Luna R, Reyes-Vazquez C, Prieto-Gomez B. Melatonin modulates cholinergic transmission by blocking nicotinic channels in the guinea-pig submucosus plexus. Eur J Pharmacol 1996; 312: 319-325.
• Benoulai-Pellissier S. Melatonin is involved in cholecystokinin-induced changes of ileal motility in rats. J Pineal Res 1994; 17: 79-85.
• Bubenik GA. The effect of serotonin, N-acetylserotonin and melatonin on spontaneous contractions of isolated rat intestine. J Pineal Res 1986; 3: 42-54.
• Harlow AJ, Weekly BC. Effect of melatonin on the force of spontaneous contractions of in vitro rat small and large intestine. J Pineal Res 1986; 3: 277-284.
• Drago F, Macanda S, Salehi S. Small doses of melatonin increase intestinal motility in rats. Dig Dis Sci 2002; 47: 1969-1974.
• Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY. Melatonin improves pain in inrritable bowel syndrome patients who have sleep disturbances: a randomized double blind placebo controlled study. Gut 2005; 54: 1402-1407.
• Lu WZ, Gwee KA, Moachhalla S, Ho KY. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a randomized double blind placebo controlled study. Aliment Pharmacol Ther 2005; 22: 927-934.
• Saha L, Malhorta S, Rana S, Bhasin D, Pandhi P. A preliminary study of melatonin in irritable bowel syndrome. J Clin Gastroenterol 2007; 41: 29-32.
• Carrillo-Vico A, Guerrero JM, Lardana PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27: 189-200.
• Konturek PC, Burnat G, Brzozowski T, Zopf Y, Konturek SJ. Tryptophan free diet delays healing of chronic gastric ulcers in rat. J Physiol Pharmacol 2008; 59(Suppl 2): 53-65.
• Spiller RC, Jankins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T-lymphocytes and increased gut permeability following acute Campylobacter enteritis and post dysenteric irritable bowel syndrome. Gut 2000; 47: 804-811.
• Shen B, Lin W, Remzi FA, et al. Enterochromaffin cell hyperplasia in irritable bowel syndrome. Am J Gastroenterol 2008; 103: 2293-300.
• Radwan P, Skrzydlo-Radomanska B, Radwan-Kwiatek K, Burak-Czapiuk B, Strzelecka J. Is melatonin involved in the irritable bowel syndrome? J Physiol Pharmacol 2009; 60(Suppl 3): 67-70.